Merck Animal Health, a division of Merck & Co. Inc., announced Feb. 13 increased investment and expansion opportunities in its U.S. manufacturing and warehousing sites, namely Millsboro, Del.
According to the announcement, the company expanded its manufacturing capacity and capabilities in Millsboro last year with additional expansion activities planned over the next few years.
“We are excited about the opportunity to bring capital improvements, expansion in our manufacturing capacity and capabilities and advanced technology to our Millsboro facility, thereby strengthening our footprint in the state and increasing our ability to fulfill customer demand for our portfolio of products,” said Bruce Lynch, Millsboro site director for Merck Animal Health. “Our Merck Animal Health business is making great strides in building our business for the future. That means we need to ensure our place as a leader in animal health with a substantial and sustainable U.S. facility footprint, which includes investment and expansion in our key facilities. As a leader in delivering innovative pharmaceuticals and vaccines to advance animal health and meet customer needs, this investment reflects our commitment in producing a range of animal health vaccines and pharmaceuticals for animal health diseases.”
Because of the company’s strong growth, broad product portfolio and enhanced manufacturing capacity and capabilities, Merck Animal Health continues to explore ways in the U.S. and globally to improve existing facilities with upgraded equipment or technology, further expand its facilities with advanced technology platforms and increase capacity and capabilities in manufacturing and warehousing to meet the rapidly growing demand and flexibility for its vaccine and biologic products, the company said.
“We are working diligently to create new ways and processes to better serve our customers and strengthen our investment in expanding our manufacturing and warehousing capacity and capabilities so that we remain a valued partner to our customers through our reliability, flexibility and responsiveness,” said Scott Bormann, vice president, North America Commercial Operations, Merck Animal Health.
Merck Animal Health is one of the largest poultry vaccine manufacturers worldwide, with products against most major pathogens and a focus on diseases affecting broilers, breeders and layers.
The company continues to invest in expanding its manufacturing facilities around the world with a recent expansion of its manufacturing, packaging and warehousing facility for blending and filling of poultry vaccines at its site in Milton Keynes, U.K.
Merck Animal Health said it strongly supports the responsible use of enhanced vaccine and pharmaceutical production platforms to improve and maintain the health of animals, as well as discovery of new tools to prevent, treat and, in some cases, even eradicate diseases.